In a first‐in‐human dose‐escalation study (CTR20180310) involving patients with relapsed/refractory solid tumors, the DCR was 100% for EGFR‐positive patients receiving doses of MRG003 at or above 1.5 mg/kg.182 In a subset analysis from another phase I study (NCT04868344) involving 39 patients with refractory advanced squamous cell carcinomas of the head and neck, colorectal cancer, and nasopharyngeal carcinoma, all patients were found to be EGFR positive.183. The gene discussed is EGFR; the disease is colorectal cancer.